ArticleThe Journal of infection2022
Influence of immune escape and nasopharyngeal virus load on the spread of SARS-CoV-2 Omicron variant.
Abstract readLetter
In one paragraph
Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID-19.Immunity, inflammation and disease · 2025Article
- Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients.PloS one · 2025Article
- Article
- RNA loads of severe acute respiratory syndrome coronavirus 2 in patients with breakthrough coronavirus disease 2019 caused by the Delta and Omicron variants.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Observational
- Review
- Article
- Viral shedding patterns of symptomatic SARS-CoV-2 infections by periods of variant predominance and vaccination status in Gyeonggi Province, Korea.Epidemiology and health · 2023Article
- Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19.Frontiers in public health · 2023Article
- A retrospective analysis of factors associated with the length of hospital stay in COVID-19 patients treated with Nirmatrelvir / Ritonavir.Frontiers in pharmacology · 2023Article
- Clinical Characteristics Profile of COVID-19 Patients with Omicron Variant Admitted in a Tertiary Hospital, Central China.International journal of general medicine · 2023Article
- Contextualizing Wastewater-Based surveillance in the COVID-19 vaccination era.Environment international · 2023Review
- Omicron Wave SARS-CoV-2 Diagnosis: Evaluation of Saliva, Anterior Nasal, and Nasopharyngeal Swab Samples.Microbiology spectrum · 2022Article
- The evaluation of an automated mariPOC SARS-CoV-2 antigen test compared to RT-qPCR SARS-CoV-2 assay and comparison of its sensitivity in Delta- and Omicron-variant samples.Influenza and other respiratory viruses · 2022Article
- Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study.The Lancet. Respiratory medicine · 2022Article
- Combining Phi6 as a surrogate virus and computational large-eddy simulations to study airborne transmission of SARS-CoV-2 in a restaurant.Indoor air · 2022Article
- Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant.Microbiology spectrum · 2022Article
- SARS-CoV-2 indoor environment contamination with epidemiological and experimental investigations.Indoor air · 2022Article
- "Lymphocyte * Neutrophil" count decreased in SARS-CoV-2 Omicron patients in Shanghai with no significant change in CRP and SAA.Journal of clinical laboratory analysis · 2022Article
- The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.Journal of virology · 2022Article
- The Omicron variant BA.1.1 presents a lower pathogenicity than B.1 D614G and Delta variants in a feline model of SARS-CoV-2 infection.bioRxiv : the preprint server for biology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Marion MigueresLaboratoire de virologie, Institut fédératif de Biologie, Hôpital Purpan, CHU Toulouse, 330 avenue de Grande Bretagne, Toulouse 31300, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse 31300, France; Université Toulouse III Paul-Sabatier, Toulouse, France. Electronic address: migueres.m@chu-toulouse.fr.
Chloé DimeglioLaboratoire de virologie, Institut fédératif de Biologie, Hôpital Purpan, CHU Toulouse, 330 avenue de Grande Bretagne, Toulouse 31300, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse 31300, France.
Pauline TrémeauxLaboratoire de virologie, Institut fédératif de Biologie, Hôpital Purpan, CHU Toulouse, 330 avenue de Grande Bretagne, Toulouse 31300, France.
Florence AbravanelLaboratoire de virologie, Institut fédératif de Biologie, Hôpital Purpan, CHU Toulouse, 330 avenue de Grande Bretagne, Toulouse 31300, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse 31300, France; Université Toulouse III Paul-Sabatier, Toulouse, France.
Stéphanie RaymondLaboratoire de virologie, Institut fédératif de Biologie, Hôpital Purpan, CHU Toulouse, 330 avenue de Grande Bretagne, Toulouse 31300, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse 31300, France; Université Toulouse III Paul-Sabatier, Toulouse, France.
Sébastien LhommeLaboratoire de virologie, Institut fédératif de Biologie, Hôpital Purpan, CHU Toulouse, 330 avenue de Grande Bretagne, Toulouse 31300, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse 31300, France; Université Toulouse III Paul-Sabatier, Toulouse, France.
Jean-Michel MansuyLaboratoire de virologie, Institut fédératif de Biologie, Hôpital Purpan, CHU Toulouse, 330 avenue de Grande Bretagne, Toulouse 31300, France.
Jacques IzopetLaboratoire de virologie, Institut fédératif de Biologie, Hôpital Purpan, CHU Toulouse, 330 avenue de Grande Bretagne, Toulouse 31300, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse 31300, France; Université Toulouse III Paul-Sabatier, Toulouse, France.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19SARS-CoV-2HumansSerologic TestsSpike Glycoprotein, CoronavirusSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19Immune escapeOmicron variantSARS-CoV-2VaccinationViral load
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.